These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 2076745)
1. Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humans. Mross K; Mayer U; Hamm K; Burk K; Hossfeld DK Eur J Clin Pharmacol; 1990; 39(5):507-13. PubMed ID: 2076745 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. Mross K; Maessen P; van der Vijgh WJ; Gall H; Boven E; Pinedo HM J Clin Oncol; 1988 Mar; 6(3):517-26. PubMed ID: 3162516 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans. Robert J; Armand JP; Huet S; Klink-Alakl M; Recondo G; Hurteloup P J Clin Oncol; 1992 Jul; 10(7):1183-90. PubMed ID: 1607922 [TBL] [Abstract][Full Text] [Related]
4. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial. de Jong J; Geijssen GJ; Munniksma CN; Vermorken JB; van der Vijgh WJ J Clin Oncol; 1992 Dec; 10(12):1897-906. PubMed ID: 1453205 [TBL] [Abstract][Full Text] [Related]
5. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. Camaggi CM; Comparsi R; Strocchi E; Testoni F; Angelelli B; Pannuti F Cancer Chemother Pharmacol; 1988; 21(3):221-8. PubMed ID: 3162849 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of doxorubicin and its active metabolite in patients with normal renal function and in patients on hemodialysis. Yoshida H; Goto M; Honda A; Nabeshima T; Kumazawa T; Inagaki J; Yamanaka N; Ota K Cancer Chemother Pharmacol; 1994; 33(6):450-4. PubMed ID: 8137454 [TBL] [Abstract][Full Text] [Related]
8. [Iodo-doxorubicin, a new anthracycline derivative. Current state of progress]. Mross KB; Langenbuch T; Burk K; Hossfeld DK Onkologie; 1990 Oct; 13(5):346-51. PubMed ID: 2082229 [TBL] [Abstract][Full Text] [Related]
9. Doxorubicin pharmacokinetics in the rabbit. Maniez-Devos DM; Baurain R; Trouet A; Lesne M J Pharmacol; 1985; 16(2):159-69. PubMed ID: 4058012 [TBL] [Abstract][Full Text] [Related]
10. Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials. Gianni L; Viganò L; Surbone A; Ballinari D; Casali P; Tarella C; Collins JM; Bonadonna G J Natl Cancer Inst; 1990 Mar; 82(6):469-77. PubMed ID: 2313718 [TBL] [Abstract][Full Text] [Related]
11. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Erlichman C; Moore M; Thiessen JJ; Kerr IG; Walker S; Goodman P; Bjarnason G; DeAngelis C; Bunting P Cancer Res; 1993 Oct; 53(20):4837-42. PubMed ID: 8402670 [TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients]. Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863 [TBL] [Abstract][Full Text] [Related]
13. Improved high-performance liquid chromatography assay of doxorubicin: detection of circulating aglycones in human plasma and comparison with thin-layer chromatography. Brenner DE; Galloway S; Cooper J; Noone R; Hande KR Cancer Chemother Pharmacol; 1985; 14(2):139-45. PubMed ID: 3971478 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Swenson CE; Bolcsak LE; Batist G; Guthrie TH; Tkaczuk KH; Boxenbaum H; Welles L; Chow SC; Bhamra R; Chaikin P Anticancer Drugs; 2003 Mar; 14(3):239-46. PubMed ID: 12634619 [TBL] [Abstract][Full Text] [Related]
15. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio. Pippa LF; Oliveira ML; Rocha A; de Andrade JM; Lanchote VL J Pharm Biomed Anal; 2020 Jun; 185():113231. PubMed ID: 32163849 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of anthracyclines. Eksborg S Acta Oncol; 1989; 28(6):873-6. PubMed ID: 2611038 [TBL] [Abstract][Full Text] [Related]
17. Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. Cusack BJ; Tesnohlidek DA; Loseke VL; Vestal RE; Brenner DE; Olson RD Cancer Chemother Pharmacol; 1988; 22(4):294-8. PubMed ID: 3168142 [TBL] [Abstract][Full Text] [Related]
18. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cusack BJ; Young SP; Driskell J; Olson RD Cancer Chemother Pharmacol; 1993; 32(1):53-8. PubMed ID: 8462124 [TBL] [Abstract][Full Text] [Related]
19. Comparative metabolism and pharmacokinetics of doxorubicin and 4'-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice. van der Vijgh WJ; Maessen PA; Pinedo HM Cancer Chemother Pharmacol; 1990; 26(1):9-12. PubMed ID: 2322993 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and metabolism of pirarubicin in advanced cancer patients. Robert J; David M; Huet S; Chauvergne J Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1289-94. PubMed ID: 3181250 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]